G. Kelly Martin


Mr. Martin is Chairman of Wren Therapeutics and has served in this position since 2018. Mr. Martin is currently Chief Executive Officer of Radius Health (Nasdaq: RDUS), a publicly quoted biopharmaceutical company committed to developing and commercializing innovative endocrine therapeutics. From 2003 to 2013, Mr. Martin was CEO of Elan Corporation plc, a pharmaceutical company focused on neurodegenerative diseases such as multiple sclerosis, Alzheimer’s, and Parkinson’s. Headquartered in Ireland, Elan operated globally and maintained several strategic partnerships including Biogen Idec and Johnson & Johnson.  The company was sold to Perrigo Company plc in 2013 for more than $8.6 billion in stock and cash. 

Mr. Martin’s professional career started in finance having spent 22 years at Merrill Lynch & Co. Inc., leading several global divisions including Debt markets, International Equities, Systems & Technology, and the International Private Banking Group. While at Merrill Lynch, Mr. Martin lived and worked in New York, Tokyo, and London.

Want to find out more?

If you would like to join the Wren team, or are interested in partnering opportunities, or have a general enquiry, contact us.

Get in touch